dc.creatorVenzon Antunes, Marina
dc.creatorLinden, Rafael
dc.creatorSchaiquevich, Paula Susana
dc.date.accessioned2022-08-02T16:58:07Z
dc.date.accessioned2022-10-15T04:39:16Z
dc.date.available2022-08-02T16:58:07Z
dc.date.available2022-10-15T04:39:16Z
dc.date.created2022-08-02T16:58:07Z
dc.date.issued2021-01
dc.identifierVenzon Antunes, Marina; Linden, Rafael; Schaiquevich, Paula Susana; Therapeutic drug monitoring in developing nations: Assessing the current state of affairs in South America; Taylor & Francis; Expert Opinion on Drug Metabolism & Toxicology; 17; 3; 1-2021; 251-254
dc.identifier1742-5255
dc.identifierhttp://hdl.handle.net/11336/163919
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4345862
dc.description.abstractTherapeutic drug monitoring (TDM) aims to offer assistance to clinicians to improve drug dosing and clinical outcomes, while minimizing the probability of serious adverse effects in routine clinical practice. Disease conditions, drug-drug and drug-herbal interactions, noncompliance, and genetic features affect the relationship between drug concentrations in the body and clinical effects. They contribute to the pharmacokinetic inter-patient variability which ultimately impactsdrug response, resulting in some patients showing lack of therapeutic effects while others experience toxicity. Thus, the identification of the sources of pharmacokinetic variability contributes to the adequacy of the dosing regimen [1]. However, performing TDM in Developing Nations as South American Countries is particularly challenging, mainly due to the lack of structure and economic aspects.
dc.languageeng
dc.publisherTaylor & Francis
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1080/17425255.2021.1859478
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/17425255.2021.1859478
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectDEVELOPING NATION
dc.subjectPHARMACOGENETIC
dc.subjectSOUTH AMERICA
dc.subjectTHERAPEUTIC DRUG MONITORING
dc.titleTherapeutic drug monitoring in developing nations: Assessing the current state of affairs in South America
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución